Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On December 31, 2019, Dr. Fatih Uckun informed Mateon Therapeutics, Inc. (the
"Company") of his intention to resign from his position as the Company's Chief
Medical Officer, effective January 6, 2020. The Company's management and Board
of Directors thank Dr. Uckun for his contributions over the past year and wish
him success in his future endeavors.
On December 6, 2019, Dr. Seymour Fein was appointed as Company's Chief Medical
Officer, effective immediately. Dr. Fein's professional activities have been
focused on drug development research for over 35 years. He has been extensively
involved in the successful evelopment of numerous drugs, biologics and medical
devices over this time leading to FDA approvals for over 20 drugs (NDAs, sNDAs,
BLAs) and devices (PMAs). Dr. Fein began his career at Hoffmann-La Roche Ltd. as
a senior research physician and was responsible for a clinical development
program that led to U.S. Food and Drug Administration (FDA) approval of
recombinant interferon-alpha for cancer treatment. Dr. Fein was also the medical
director of Bayer Healthcare Pharmaceuticals (U.S.) where he was responsible for
therapeutic areas including gastroenterology, oncology, and cardiology. He later
served as medical director for Rorer Group (now part of Sanofi) and Ohmeda (now
part of Baxter). Dr. Fein founded and has been managing partner of a clinical
and regulatory consulting organization and has worked closely with the Division
of Gastroenterology and Inborn Errors Products at the FDA. He has participated
in the development of and FDA approval of numerous drug products in many
therapeutic areas. Dr. Fein has successfully overseen entrepreneurial drug
development leading to the FDA approval of two orphan drug products in the field
of gastroenterology.
Dr. Fein received his B.A. degree from the University of Pennsylvania and his
M.D. degree with honors from New York Medical College. He completed a three-year
residency in internal medicine at Dartmouth and a three-year fellowship in
medical oncology and hematology at Harvard Medical School, where he served as an
instructor of medicine during his final fellowship year. Dr. Fein is
board-certified in both oncology and internal medicine.
-2-
© Edgar Online, source Glimpses